References
1. Borgsteede S, Geersing TH, Tempels-Pavlica Z. Other excipients than
PEG might cause serious hypersensitivity reactions in COVID-19 vaccines.
Allergy. 2021.
2. Ludger Klimek, Natalija Novak, Beatriz Cabanillas, et al. Allergenic
components of the mRNA-1273 vaccine for COVID-19: possible involvement
of polyethylene glycol and IgG-mediated complement activation. Authorea.
January 01, 2021.
3. Lukawska, J., et al., Anaphylaxis to trometamol excipient in
gadolinium-based contrast agents for clinical imaging. J Allergy Clin
Immunol Pract, 2019. 7(3): p. 1086-1087.
4. Castells MC, Phillips EJ. Maintaining Safety with SARS-CoV-2
Vaccines. N Engl J Med. 2020 Dec 30. doi: 10.1056/NEJMra2035343.
5. Badiu I, Geuna M, Heffler E, Rolla G. Hypersensitivity reaction to
human papillomavirus vaccine due to polysorbate 80. BMJ Case Rep. 2012
May 8;2012:bcr0220125797.
6. Stone CA Jr, Liu Y, Relling MV, Krantz MS, Pratt AL, Abreo A, Hemler
JA, Phillips EJ. Immediate Hypersensitivity to Polyethylene Glycols and
Polysorbates: More Common Than We Have Recognized. J Allergy Clin
Immunol Pract. 2019;7:1533-1540.e8.
Figure 1. Active components and excipients listed in BNT162b2,
mRNA-1273, and AZD1222 vaccines. The principles of the PEGylated-lipid
nanoparticles as a delivery system for the mRNA in BNT162b2, mRNA-1273
vaccines are depicted in the upper part together to the
replication-deficient adenovirus ChAdOx1 vector containing the gene of
the glycoprotein spike (S) antigen of SARS-CoV-2 for the AZD1222
vaccine. Potential triggers of allergic reactions are indicated in red
color in the excipient lists of each vaccine.